BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 6590116)

  • 1. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells.
    Gustavsson A; Olofsson T
    Cancer Res; 1984 Oct; 44(10):4648-52. PubMed ID: 6590116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
    Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
    Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
    Colly LP; Peters WG; Willemze R
    Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
    Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of glutathione transferase pi as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia.
    Tidefelt U; Elmhorn-Rosenborg A; Paul C; Hao XY; Mannervik B; Eriksson LC
    Cancer Res; 1992 Jun; 52(12):3281-5. PubMed ID: 1596886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous exposure to drugs.
    Park CH; Wiernik PH; Morrison FS; Amare M; Van Sloten KV; Maloney TR
    Cancer Res; 1983 May; 43(5):2346-9. PubMed ID: 6572563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GM-CSF enhances sensitivity of leukemic clonogenic cells to long-term low dose cytosine arabinoside with sparing of the normal clonogenic cells.
    De Witte T; Muus P; Haanen C; Van der Lely N; Koekman E; Van der Locht A; Blankenborg G; Wessels J
    Behring Inst Mitt; 1988 Aug; (83):301-7. PubMed ID: 3071344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An in vitro chemotherapy sensitivity test on leukemic colony-forming cells (L-CFU) and its clinical evaluation].
    Moriyama Y; Urushiyama M; Hirosawa H; Koyama S; Takai K; Fujiwara M; Kishi K; Takahashi M; Sakai C; Sanada M; Shibata A
    Gan To Kagaku Ryoho; 1982 Oct; 9(10):1749-54. PubMed ID: 7184371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of clonogenic assay for induction and duration of complete remission in acute myelogenous leukemia.
    Marie JP; Zittoun R; Delmer A; Thevenin D; Suberville AM
    Leukemia; 1987 Feb; 1(2):121-6. PubMed ID: 3478535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen.
    Tafuri A; De Felice L; Petrucci MT; Mascolo MG; Ricciardi MR; Ciliberti C; Martelli MP; Petti MC
    Cytokines Mol Ther; 1995 Dec; 1(4):301-7. PubMed ID: 9384683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K; Nayak R; Grant S
    Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
    Marie JP; Thevenin D; Zittoun R
    Nouv Rev Fr Hematol (1978); 1985; 27(3):163-7. PubMed ID: 3862071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy sensitivity assessment of leukemic colony-forming cells with in vitro simultaneous exposure to multiple drugs: clinical correlations in acute nonlymphocytic leukemia.
    Park CH; Amare M; Morrison FS; Maloney TR; Goodwin JW
    Cancer Treat Rep; 1982 Jun; 66(6):1257-61. PubMed ID: 7083232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Differentiation induction of myeloid leukemia cells by glucocorticoid--the differentiation induction effect in vitro and in vivo].
    Nakamaki T; Sakashita A; Sano M; Hino K; Suzuki K; Tomoyasu S; Tsuruoka N
    Rinsho Ketsueki; 1989 Feb; 30(2):149-57. PubMed ID: 2746870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.